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Amniotic Growth Factor induced bone formation in a mouse ex-vivo model  
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Cells, growth factors and scaffold are the 3 fundamental factors currently proposed 
necessary for tissue regeneration. The use of these components has to be orchestrated 
precisely for ideal functional tissue formation. Growth factors enhance cellular activities 
that may lead to angiogenesis, cell proliferation and extracellular matrix biosynthesis. Due 
to the complexity of biochemical reactions a single growth factor may have limited effect. 
In order to explore a mixed profile of growth factors, a new biomaterial containing multiple 
 
 vi
growth factors derived from human Amniotic Membrane was chosen to compare with a 




To compare the potential for enhanced bone formation by a morselized amniotic membrane 
suspension (AmnioSpark) with a known single cytokine PDGF-BB (GEM21,Lynch) under 
ex-vivo calvaria culture conditions. 
 
Materials and Methods: 
45 Calvaria from 7-9 day neonatal CD-1 mice were surgically harvested under sterile 
conditions. The calvaria were split through the mid sagittal  suture to create 90 test 
specimens. A 2mm diameter critical size  defect was created by biopsy punch thru the 
center of each calvarial specimen. This defect was bridged with a non-crosslinked type I 
collagen membrane of the same diameter to act as a scaffold. To compare AmnioSpark 
(AGF) potential for tissue regeneration against a known single cytokine PDGF-BB, the 
calvarial specimen were divided into six experimental groups: 1) Defect only, 2) Defect + 
scaffold, 3) Defect + scaffold + a single dose  of  (rhPDGF-BB ) a known bone stimulant,  
4) Defect + Scaffold + 4 doses (day 0,3,5,7) of ( rhPDGF-BB), 5) Defect + scaffold + a 
single dose  of  (AGF) and 6) Defect + scaffold + 4 doses (day 0,3,5,7) of  (AGF). Each 
test group had  (N=5). A unique  static tissue culture method was used with DMEM 
medium supplemented with ascorbic acid (150 ug/ml)  and bovine serum albumin (5 
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mg/ml) without fetal calf serum to enhance bone formation for up to 7 weeks. Culture 
medium was changed every 2 days after day 3 and the harvested media was used for the 
following analyses: A) Alkaline phosphatase (ALP) as an osteoblastic activity indicator, 
and B) Tartrate Resistant Acid phosphatase (TRAP) as an osteoclastic bone remodeling 
activity indicator1. Macro photography and Scanning electron microscope (SEM) image 
analysis at different magnifications was performed to evaluate surface conditions. 
Histological analysis was performed with light microscope images on standard 4 um 
sections using  H&E, Tri chrome, Picrosirius red and a fluorescence stain for RUNX2 as 
an osteoblast marker. 
Results: 
With a single  dose of test material ALP activity in the AGF group was significantly higher 
at 5 and 7 days. In addition ALP activity was significantly higher compared to all groups 
for up to 3 weeks post-application in the multiple dose AGF group (P<0.05). In contrast 
there was a dramatic decline in ALP in all other groups within the first week. TRAP activity 
was not detectable in any group. SEM images showed that osteoblast like cells accumulated 
and new tissue formation occurred over the surface of the scaffold obliterating the 
defect/membrane interface at 21 days with the AGF stimulus while in the  PDGF-BB group 
the scaffold was still distinguishable from surrounding bone with no new tissue formation 
or cell migration . Histologic images confirmed an organized distribution of cells along the 
surface of the scaffold and new bone formation around the periphery of the defect in the 
AGF group (FIG42), while no bone formation or cell migration occurred in PDGF-BB 
 
 viii 
group  (FIG 35-38). Further diagnostic stains confirmed the presence of active osteoblasts 
(RUNX2)and the production of collagens I and II ( Masson Tri Chrome and PSR). 
Conclusion:                                                                                                    
Our results indicate that growth factors from amniotic extract (AGF) have the potential to 
enhance calvarial bone regeneration under an ex-vivo culture condition. These findings 
suggest that AGF could be a candidate for use as a new type of therapeutic material for 
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The management of new bone formation remains one of the crucial issues in implant site 
development and periodontology. Recent research has shifted toward understanding the factors 
that regulate the behavior of  osteoblasts and bone formation and how different regulation 
mechanisms and cytokines  interact with each other and with the cells. The goal is to develop an 
innovative treatment modality to enhance bone regeneration.2 
 
Cytokines are key factors in understanding  the stream of events necessary for development and 
healing of osseus tissue. They may interact directly with the cells that secreted them (autocrine) or 
neighboring cells (paracrine). When a cytokine interacts with the cell receptor, cellular signals  
may trigger events such as proliferation which results in an increase of the number of cells through 
cells division, adhesion which is the process by which cells form contacts with each other or with 
their extra cellular matrix through specialized protein complexes or differentiation which is the 
process by which dividing cells change their functional or phenotypical type. Cytokines also 
stimulate physiologic responses involved in angiogenesis, wound healing, and organism early 
development and these collectively are categorized as growth factors. Several individual growth 
factors have been approved for clinical uses in bone regeneration. These include human growth 





The effect of these  factors is still not well understood when applied to bone regeneration due to 
the lack of a model system that  mimics the interaction that occurs in normal bone tissue compared 
to a two dimensional cell culture. To evaluate the effect of growth factors in regeneration the 
minimum requirements of an ex-vivo system would be to have a multicellular well-orchestrated  
periosteal and endosteal cell layers with the natural architecture of organic and calcified inorganic 
matrix surrounding osteocytes in lacunae. This organ culture would need the capacity to replicate 
cellular reactions separately or in combination with cells derived from hematopoietic lineage or 
mesenchymal origin. Such a  3D Ex-vivo model was described by Salih et.al  which closely 
simulates in vivo natural bone healing phenomena and contains the biological components of live 
bone. According to the authors, this model has the capacity  to test bone resorption or bone 
formation and parts of wound healing phenomena can be explored in the presence or absence of 
















Amniotic membrane: The inner most layer surrounding the fetus 5 
  
 
Figure 1. The amniotic membrane structure. 
In humans, the placenta is formed from a portion of the human embryo. It’s outer surface acts as 
the interface of the embryo with the uterine wall and it provides the transportation system of 
nutrients from mother to fetus. The placenta development starts within 6-7 days after fertilization. 
The base of the placenta is discoid in shape, has a diameter of 15-20 cm and 2-3 cm thickness and 
is integrated with the uterine wall containing the umbilical cord. The remainder continues to 
develop as a fluid filled sack which envelops the fetus and consists of two layers: The amnion 
membrane which is  the inner layer closest to the fetus and is composed of epithelium on a 
basement membrane  a compact layer, a fibroblast layer, and finally a spongy layer which 
interfaces with an outer structure the chorion.  This second outer layer facing the remaining surface 






The epithelium of the amnion is a single cell layer and consists of cuboidal and columnar 
epithelium cells that covers the inner surface in direct contact with the amniotic fluid. The amniotic 
compact layer  is acellular and contains fibers of collagens I and III and fibronectin. The adjacent 
fibroblast layer contains mesenchymal stromal cells, and monocyte like cells. The spongy layer is 
the loosely connected interface with chorion which allows the ease of separation of the amniotic 
membrane from the chorion with blunt dissection. The amniotic membrane is avascular and has 
no nerves. It’s nutrition is derived directly from amniotic fluid by diffusion.6 
 
 






The amniotic membrane has a huge potential for tissue regeneration. It has the three prerequisites  
suggested for tissue engineering: scaffold, mesenchymal stem cells, and growth factors. 
The amniotic membrane is a biocompatible material which possesses the ideal prerequisites for a 
wound dressing material. It is not toxic or cancerous and it does not create an immunological 
response. 8 Koizumi et al, reported that mitogenic growth factors found in the amniotic membrane 
included Epidermal growth factor (EGF), Hepatocyte growth factor (HGF), and Keratinocyte 
growth factor (KGF). They also found that removing cells from the amniotic membrane did not 
affect the amount of  bFGF and TGF-b. 9RNA extraction has demonstrated the presence of bFGF.10 
Koob et al, used ELISA assays on amniotic membrane extracts to show the presence PDGF-BB, 
PDGF-AA, bFGF, HGF, VEGF, and EGF. 11 Addition of single growth factors such as IGF-1 or 
TGF-b systemically and locally in rats  in-vivo experiments produced positive effects on healing 
















The addition of a morselized Amniotic membrane suspension which is reported to contain multiple 
growth factors  might increase tissue regeneration when compared to application of a single  known 
in vivo growth factor stimulant Platelet Derived Growth Factor (PDGF-BB). The null hypothesis 





Specific Aim1: Document the osteogenic potential of a morselized amniotic membrane suspension 
(AmnioSpark amnion growth factor liquid) when compared with a known isolate of PDGF-BB 
in critical size  bone defects in a 3D ex-vivo calvaria tissue culture. 
 
Specific Aim2: Test the effect of a pulsed application of these same potential stimulants  under the 















Bone is a living mineralized connective tissue that plays a critical role in the mechanical 
functions of the body. It supports and protects soft tissue and act as a reservoir for calcium and 
phosphate. In the case of the dental organ, it supports teeth. It is composed of organic and 
inorganic parts. The organic part is mainly collagen type I while the inorganic mineral 
compartment consists of   a substituted carbonaceous calcium hydroxyapatite which gives the 
bone rigidity. Bone has the ability to adapt and respond to physiological and mechanical 
stimuli.1314 
Individual bones are structurally organized for their various roles with  an outer dense layer and 
an inner less dense structure containing the soft connective tissue known as the marrow. The 
outer dense compact layer ,referred to as the cortex, contributes  about 80% of the bone mass. 
Inside the cortical shell is a bracing framework of trabecular or cancellous bone which 
contributes about 20% of the bone mass. Bone can be divided according to shape into long, 
short, flat, irregular, and sesamoid. Furthermore, it can be divided into two types according to its 







The external surface of bones is covered by a fibrous membrane called the periosteum. The 
periosteum often has two layers. The inner cellular  layer is responsible for the development of a 
new bones size in fetal life and early childhood as well as increasing the length and width of a 
long bone. This function is due to the numerous osteoprogenitor cells in this layer. The fibrous 
layer is essentially protective and serves as an attachment place for muscle and fasciae. It is 
composed of fibroblasts, and their progenitor cells. Inside the bone,  separating  the marrow 
spaces from the mineral compartment is a  liner cell membrane. The marrow contains a soft 
connective tissue compartments that help in healing fractures and provides progenitor 
hematopoietic stem cells.13 The calvarium is thin plate of bone which covers the brain. In the 
adult this usually consists of 2 plates of cortical bone with a thin marrow compartment. In 

























Bone tissue has four kinds of cells: osteoblasts, osteocytes, osteoclasts and liners cells. Each type 







They are located at the bone surface and form 4-6% of the total bone cells. They are protein 
synthesizing cells with extensive rough endoplasmic reticulum and prominent Golgi apparatus. 
They secrete type I collagen to form the bone matrix in addition to, osteopontin, osteocalcin, and 
sialoprotein. Osteoblasts  secrete alkaline phosphatase during the mineralization process and 
therefore  osteoblastic activity can be measured by quantification of  alkaline phosphatase 
activity.15  
Osteocytes: 
Osteocytes are the longest living cells in the bone with a life span of up to 25 years. 
They make up between 90-95% of the total bone cells. They are thought to be terminally 
differentiated and  can be found in small lacunae or holes within  the mineralized bone 
compartment. They communicate through cell  projections within small canals (the canaliculi) 
that terminally connect with the lining cells on the bone surface, with vascular supply and with 
other osteocytes to form a complex net within the mineralized bone. They are sensitive to 
mechanical stimuli , regulate calcium homeostasis and orchestrate bone turnover through 







Osteoclasts are terminally differentiated multinucleated giant cells. They are derived from 
multiple fused mononuclear cells of the hematopoietic stem cell lineage the macrophage. 
Osteoclasts formation is induced through RANKL/RANK interaction and  produce tartrate 
resistant acid phosphatase (TRAP and cathepsin K) during resorption and this TRAP levels can 
be used to measure osteoclast activity.13 
 
Bone lining cells: 
Bone lining cells are dormant osteoblasts that cover the marrow surface of  quiescent bone. 
These cells form a shield between the marrow compartment and the bone matrix. They are also 
involved in regulation of osteoclastogensis through production of osteoprotegrin (OPG) and the 
receptor activator of nuclear factor kappa-b ligand (RANKL).13 
 
Bone Formation: 
Bone formation starts during embryogenesis thru two processes: direct and indirect ossification. 
In direct ossification such as in the formation of the skull, aggregated mesenchymal progenitor 
cells differentiate directly into osteoblasts in a process called intramembranous ossification. 
These osteoblasts release a loose organic matrix around blood vessels which then mineralizes. 
Osteoblasts are trapped within the newly forming bone matrix to become osteocytes and during 
this encapsulation they form the cytoplasmic extensions which are trapped in  canaliculi that 
allows them to maintain contact with other cells. Intramembranous ossification is found in 






Indirect ossification known as endochondral ossification starts with differentiation of 
chondrocytes to produce a hyaline cartilage model of the new bone. This is characteristic of the 
long bones such as the tibia and humerus. Vascular buds with surrounding  bone progenitor cells 
invade the cartilage model and create a marrow space. Eventually these osteoprogenitor cells 
differentiate to osteoblasts and gradually replace the cartilage with mature bone. This process 





























Wound healing (soft and hard tissues): 
Soft tissue : 
Immediately after an incision in the soft tissue, platelets within the blood vessels are exposed to a 
perivascular environment. They attach to wound margins and subendothelial collagen fibers and 
stimulate a clotting cascade that transforms prothrombin to thrombin, which then converts 
soluble fibrinogen to fibrin.17,18 
The fibrin net acts as a scaffold and with the deposition of more platelets, red blood cells, 
circulating polymorphonucleocytes (PMNs), and macrophages give rise to a vascular plug called 
a blood clot. Those cells entrapped in the mesh induce an overexpression of multiple cytokines 
or growth factors such as, platelet-derived growth factor (PDGF), vascular endothelial growth 
factor (VEGF), and transforming growth factor (TGF)-ß which stimulate cells in  tissues 
surrounding the wound and attract more macrophages and PMNs from adjacent dilated 
venules.19 
Fibroblasts go through several phenotypic changes. Clark described these phases as: 
proliferation, migration, production, and transformation to myofibroblasts. The fibroblast 
proliferation phase occurs later than in epithelial cells, in the first 2 to 3 days. In the migration 
phase which starts by days 4 to 7, the fibroblasts invade the provisional matrix space and deposit 







Wound healing in bone goes through four temporal phases these are: hematoma formation, 
inflammation, angiogenesis and callus formation. Multiple processes occur simultaneously 
during bone formation that lead to the production of  matrix, angiogenesis and calcified matrix 
formation. The major cytokines involved in controlling the wound healing cascade are 
interleukin 1, interleukin 6, transforming growth factor (TGFb), insulin like growth factor (IGF),  
Fibroblast growth factor (FGF), Platelet derived growth factor (PDGF), and bone morphogenetic 
protein (BMP). TGFb is released from platelets, bone and cartilage extracellular matrix and is a 
pleiotropic growth factor that acts as a stimulant for mesenchymal cells. BMPs are released from 
osteoprogenitor cells, osteoblasts and bone extracellular matrix and act as a morphogen for 
mesenchymal cells to differentiate into chondrocytes, osteoblasts, and osteoprogenitor cells to 
differentiate into osteoblasts. FGF is released from macrophages, mesenchymal cells and 
chondrocytes and acts as proliferative factor for mesenchymal cells, chondrocytes and 
osteoblasts. IGF is released from bone matrix, osteoblasts and chondrocytes and it is a 
proliferative and differentiation factor for osteoprogenitor cells. PDGF is released from platelets 
and osteoblasts and is a proliferative factor for mesenchymal cells and osteoblasts.  
 
In the first hour after fracture, degranulation of platelets occurs after hematoma formation 
releasing TGFb and PDGF. IL-1 and IL-6 are released by inflammatory cells. BMPs are 
expressed by mesenchymal cells within 24 hours . Endosteal cells start to express an osteoblastic 
phenotype and form bone. Osteoprogenitor cells  present under the periosteum are ready to begin 




osteocytes and mesenchymal cells into osteoprogenitor cells. From 4-7 days there is an increase 
in the expression of mRNA of type II collagen from cells that have a chondrocytic phenotype. 
Soft callus forms at the edges of the bone defect. From 6-10 days, hard callus contains 
osteocalcin and there is high cellular proliferation. Osteopontin is expressed in both osteocytes 
and osteoprogenitor cells. From 11-20 days proliferation ceases and no expression of collagen 
type II is present. The cartilage starts to calcify. The soft callus takes the structure of a growth 
plate with primary and secondary spongiosa present .From 21-25 days the structure is now 
woven bone and there is no more cellular proliferation. Solid union of fracture is present within 


















Collagen as a bridge/scaffold: 
 
 
There are 2 types of collagen membrane produced to assist in bone regeneration. The first  is a 
natural collagen membrane that is not cross-linked has the structure of the native tissue and 
preserves its original properties such as tear and pull resistance and good adaptation to different 
surfaces. The major drawback related to the natural non crosslinked collagen membrane when used 
in guided tissue regeneration as a barrier is the fast resorption rate in a clinical setting.23 To resolve 
this degradation issue cross-linking of collagen membrane was introduced . Greater cross linking 
reduces the rate of resorption .24 Rothamel et al. however observed the different effects of natural 
vs multiple cross linked collagen membranes and stated that natural collagen membrane had the 
highest vascularization and tissue integration. They also noted that  some of the cross linked 
samples had foreign body reactions during resorption.25  As a scaffold the non cross-linked 
collagen membrane would be preferred. 
 
Critical size defect: 
A critical size defect in bone is defined  as the size of an osseous defect that does not heal 
spontaneously  with bone during the lifetime of the animal except with the addition of a 
regenerative material or a scaffold. The critical size defect should be defined for each  to animal 
age, size, site and model.  
X wu et al, evaluated the healing potential of neonatal mouse parietal defects in different culture 




sizes of defect: .08, 1.0 and 1.5 mm defects. A 1.5 mm diameter defect was found to be the critical 





Bone morphogenetic proteins (BMP) used in periodontal regeneration have shown  the potential 
to induce ectopic bone and cementum formation.28,29Animal studies have shown improved 
regenerative outcomes when BMPs were used for treating periodontal defects.29–31The first human 
study used Osteogenin (BMP-3) blended with DFDBA.32This combination significantly improved 
regeneration of new periodontal tissue in submerged teeth. This agrees with previous animal 
studies showing improved regenerative outcomes from the use of these bone morphogenetic 
proteins. Interestingly, ankylosis occurred in 15 of 17 dogs after treatment with BMP-2 but not 
withBMP-7.31 Growth factors may act as a differentiation factor or mitogen on regenerating 
periodontal tissue. Growth factors include platelet derived growth factor (PDGF), insulin like 
growth factor (IGF), transforming growth factor-ß (TGF-ß), and fibroblast growth factor (FGF). 



















PDGF Strong Strong Moderate Not determined 
EGF Slight Slight Inhibitory Inhibitory 
TGF-b None Inhibitory Moderate Not determined 
IGF-I Strong Strong None Strong 
PDGF+IGF-I Strongest Strongest  Not determined Not determined 





Figure 4 Growth factors are Proteins which cells secrete and interact directly with itself (Autocrine) 













Platelet derived growth factor (PDGF): 
 
Platelet derived growth factor (PDGF) is a heterodimeric or homodimeric protein containing the 
A and B poly-peptide chain (PDGF-AA, -BB, and –AB).34 PDGF has two receptors;  the Alpha 
receptor which binds all three dimeric forms with equally affinity, and the Beta receptor which 
binds to PDGF-BB with highest affinity.35 PDGF is contained in platelets and also produced by 
osteoblasts and is known to be stored in the bone matrix. It has a 3 fold increase mitogenic effect 
on osteoblastic cells in vitro in rat calvaria, human cells, and rat cell cultures.36–39 PDGF has a 
marked chemotactic effect on osteoblasts, monocytes, and fibroblasts. Recombinant Human 
Platelet derived growth factor (rhPDGF-bb) showed the most potent chemotactic effect at low 
concentrations. The maximum effect was seen at 0.1 ng/ml. PDGF increased collagen synthesis 
by 8% compared to control.40–42  
 
PDGF also plays a role  in bone repair by inducing osteogenesis in vivo.43 In a human healing 
fracture site, PDGF was  detected at early stages in a fracture hematoma. PDGF-BB mRNA was 
detected in osteoblasts.44Tsukamoto et al., demonstrated that PDGF-BB induced a chemotactic 
effect on osteoblast like cells. Their data also showed a mitogenic effect on these cells and 






Animal study effects PDGF: 
 45 Nash et al, studied the effect of PDGF-BB on osteotomies made in rabbit tibias. They observed 
increased amount and density of callus formation in the group treated with PDGF. The test group 
but not the untreated and controls healed enough to have matching strength to the non-operated 
side.46 Systemic administration of PDGF-BB in estrogen-deficient rats increased both cancellous 
and cortical bone density and prevented loss of bone induced by overectomy.47  Simion et al,48 
combined rhPDGF-BB with a bovine block graft to regenerate vertical bone defects in foxhounds. 
Their results provided a proof of principle that PDGF-BB has the potential to significantly 
regenerate new bone (75% defect fill) compared to their collagen membrane and bone graft control 
(25% defect fill). Their histological sections showed accelerated resorption and remodeling of the 
























 Nevins et al. compared the osteogenic potential of rhPDGF-BB incorporated in bone 
allograft (DFDBA) to bovine bone in collagen in 9 adult patients with 15 advanced periodontal 
defects. This study was the first to show regeneration of bone, PDL, and cementum in human of 
class II furcation defects. Their results show significant clinical attachment gain of 3.20 mm 
furcation and 6.17 mm  in infrabony defects.49 In a multicenter randomized controlled trial, Nevins 
et al. assessed the safety and efficacy of rhPDGF-BB for the treatment of periodontal defects. The 
sample size was 180 patients with 4 mm or more intrabony defects and treated with either 0.3 
mg/ml of PDGF-BB, 1 mg/ml of PDGF-BB, or Beta-tricalcium phosphate (ß-TCP) with buffer. 
This study demonstrated that rhPDGF-BB could be safely used in treatment of human periodontal 
defects. Furthermore, the use of rhPDGF-bb at the 0.3 mg/ml dose improved bone fill significantly. 
They also reported clinical attachment gain of 3.8 mm compared to 3.3mm in group 3.50 Nevins et 
al, also tested the potential for improved bone regenerative outcomes in patients undergoing 
maxillary sinus lift using PDGF-BB mixed with anorganic bovine bone mineral (ABBM). They 
reported accelerated resorption of the normally slow resorbing xenograft when the matrix was 
saturated with PDGF-BB which was then replaced with newly formed bone.51  
 
The encouraging results of growth factor mediated regeneration raised a question of  the potential 
effect of multiple growth factors on the regeneration of periodontal defects? One of the candidates 





Amnion Growth Factors: 
Studies using the Amniotic membrane  
Werber et al, treated 20 chronic soft tissue wounds in diabetic patients with amniotic 
membrane and amniotic fluid. Ninety percent (90%) of the patients demonstrated 100% 
closure within the 12-week observation compared to 12% wound healing in 3 months in a 
previous study with different treatment modalities.52Liu et al investigated the use of 
amniotic membrane as a scaffold for bone marrow mesenchymal stem cells in treating 
articular cartilage defects. Their results show that amniotic membrane can be used 
successfully as a scaffold or a carrier for mesenchymal cells.53 Tang et al,  evaluated the 
effect of amniotic membrane on bone marrow mesenchymal stem cells and bone 
regeneration. Cell proliferation was increased significantly in the amniotic membrane 
group compared to cells seeded in a pure collagen scaffold.  Osteogenic differentiation of 
Bone marrow stem cells increased significantly compared to collagen scaffold group when 
measured by Alkaline phosphatase, Osteopontin, and osteocalcin were also measured. 
These studies suggested the osteogenic potential of the amniotic membrane.54 
 
Preparation of Amniotic membrane as wound dressing:  
Aseptic technique must be utilized in the preparation of the amnion membrane. First, the placenta 
should be washed with saline and decontaminated with antibiotic repeatedly to remove potential 
pathogens. Then a cut is made close to the umbilical cord to facilitate blunt dissection to separate 
the amnion membrane from the chorion. Membrane pieces are washed to remove blood or blood 
clots. The amnion membrane is then cut into small pieces and preserved with gentle non-thermal 







Figure 5 Amniotic membrane is bluntly separated from chorion membrane 
 





Figure 7 Amniotic membrane is reduced in size for certain applications 
 
The product AmnioSpark preparation is morselized into micro pieces (there was no documentation 
of size available) which cannot be seen in the solution. The solution appears foggy from the 
morselized amniotic membrane which is suspended in plasmalyte with a concentration of 25mg 
per milliliter.55 It is suspected that the resection increased surface exposure which could contribute 
















Material and Methods 
  
In vitro calvaria tissue culture three-dimensional (3D) condition model: 
 
45 Calvaria were harvested from 7-9 day neonatal CD-1 mice (Charles River Laboratories, MA) 
under sterile conditions, trimmed and then cut in half through the mid sagittal suture. 90 Calvarial 
plates were rinsed with culture medium and each half was placed over a stainless-steel mesh in 
one well of a six well plate (Sigma Aldrich Co., SIAL0516 Sigma) containing 1.5 ml of bone 
culture medium and incubated at 37ºC and 5% CO2. (figure6-8) (For 21,29 and 48 days) 
The calvaria culture medium included Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-
Aldrich, Co.) supplemented with 1% Penicillin-streptomycin solution, 5% (5mg/ml) Bovine 
Serum Albumin (BSA), and (150µg/ml) ascorbic acid (Sigma-Aldrich Co.)  without any Fetal Calf 
Serum as described in the protocol.41  
We created a 2 mm diameter defect in the middle of each calvarial test specimen which a has 
proven to be a critical size in neonatal mice in experiments and previous studies from our lab.26  
This circular defect was filled with a non-cross linked collagen membrane disc made with the same 
punch used to create the bone defect. This  served as a scaffold to bridge the defect area. Ten (10)ul 
                                                        
1 The lack of (FCS) allows for clear observation of the effect of the added factors on bone biology either to 
respond with osteoblast directed bone formation or osteoclast-osteocyte directed bone resorption. In our 
investigation, the formation phase was stimulated by the addition of ascorbic acid, which primes osteoblasts 





of growth factor was added at designated times directly over the scaffold (figure 11). The volume 
of growth factor added was determined by calculating   the volume of soaked collagen membrane 
(Radius =1, Height=1. Total volume = 9.8 mm3 . The surrounding media was collected every other 
day and new media was added. 
 
 





Figure 9 Calvarium was trimmed and washed in culture medium 
 












Figure 11. Experimental model:2mm critical size defect was made approximately centered. 
Defect is filled with same size collagen membrane and growth factors were added to the center 













Pretreatment test: 2 types  of  processed collagen membrane. 
 
A preliminary trial tested 2 different types of collagen membrane for their marginal adaptation. 
OraTape is a non-crosslinked collagen membrane (Salvin co.,) and mimics a natural collagen 
membrane while  OraMEM  is crosslinked collagen membrane (Salvin co.,). Media was changed 
every 2 days after the first 3 days ( which was required for stability of the scaffold interface. The 
recovered media was then stored at 4℃ for chemical and biochemical analysis. At 13 days, both 
experiments were terminated and the calvaria were analyzed microscopically to analyze for contact 
between the collagen membrane and the defect periphery. The results showed closer adaptation of 
the non-crosslinked membrane to the edges of the defect due to the expansion after hydration. 
Since this  close contact best conformed to our desired scaffold/bridge effect for cell migration 









1: 21 days trail :Experimental trials to compare the effect of Amnion growth factors (AGF) vs 
(PDGF-BB). 
 
To compare AGF vs PDGF-BB potential of Bone regeneration, we tested six experimental groups:  
1) Defect only, 
2) Defect + scaffold only 
3) Defect + scaffold + single growth factor (rhPDGF-BB) (GEM21, Lynch). Single dose. 
4) Defect + scaffold + single growth factor (rhPDGF-BB) (GEM21, Lynch). Multiple dose (day 0,3,5,7) 
5) Defect + scaffold +  AGF  (AMNIOSpark, Salvin). Single dose 
6) Defect + scaffold +  AGF  (AMNIOSpark, Salvin). Multiple dose (day 0,3,5,7) 
See figure 12.  (N=5) for each subgroup with a total of (N=30) for all groups. Calvaria were fixed after day 
21 with 4% formaldehyde for 48 hours then, preserved in 70% EtOH at 4 °C. Recovered changes of media 






Figure 12 Experiment design: Each group had (N=5). Cultured media was harvested on days 
3,5,7…21 days. Growth factors were added on day 0 for the single application groups and on days 
























2: 29 days trial: Experimental trials to test the effect of Amnion growth factors vs PDGF. 
 
To compare AGF vs PDGF-BB potential of Bone regeneration, we divided the calvaria into six 
experimental groups:  
1) Defect only, 
2) Defect + scaffold only 
3) Defect + scaffold + single growth factor (rhPDGF-BB) (GEM21, Lynch). Single dose. 
4) Defect + scaffold + single growth factor (rhPDGF-BB) (GEM21, Lynch). Multiple dose (day 0,3,5,7) 
5) Defect + scaffold +  AGF  (AMNIOSpark, Salvin). Single dose 
6) Defect + scaffold +  AGF  (AMNIOSpark, Salvin). Multiple dose (day 0,3,5,7) 
See figure13. (N=5) for each subgroup with a total of (N=30) for all groups. Calvaria were fixed after day 







Figure 13 Experiment design: Each group had (N=5). Cultured media was harvested on days 
3,5,7...21 days. Growth factors were added on day 0 for the single application groups and on days 





















3: 49 days trial: Experimental trials to compare the effect of Amnion growth factors 
vs PDGF for long term effects. 
To evaluate AGF vs PDGF-BB potential of bone regeneration, we tested six experimental groups:  
1) Defect only, 
2) Defect + scaffold only 
3) Defect + scaffold + single growth factor (rhPDGF-BB) (GEM21, Lynch). Single dose. 
4) Defect + scaffold + single growth factor (rhPDGF-BB) (GEM21, Lynch). Multiple dose (day 0,3,5,7) 
5) Defect + scaffold +  AGF  (AMNIOSpark, Salvin). Single dose 
6) Defect + scaffold +  AGF  (AMNIOSpark, Salvin). Multiple dose (day 0,3,5,7) 
 
See  figure 14. (N=5) for Group with a total of (N=30) for all groups. Samples were fixed at day 49 with 







Figure 14 Experiment design: Each group had (N=5). Cultured media was harvested on days 
3,5,7...49 days. Growth factors were added on day 0 for the single application groups and on days 


















2. Biochemical analyses:  
 
1: Quantitative measures of alkaline Phosphatase (ALP) and tartrate 
resistant acid phosphatase (TRAP)activity from calvarial bones media: 
A. Alkaline phosphatase (ALP): 
Alkaline phosphatase is an enzyme secreted by osteoblasts and used as a marker for bone 
matrix formation. ALP assay allows for the quantification of alp enzyme secretion via 
pNPP substrate. ALP assay was carried out with 1mM MgCl2 with 0.2 Tris-HCL (PH=9.5) 
 
B. Tartrate resistant acid phosphatase (TRAP):  
The Trap enzyme activity of calvarial bone cells was analyzed as a marker for possible 
bone resorption1 . Acid phosphatases (ACP) are present in many cells and tissues such as 
liver, kidney and osteoclasts and osteocytes. The assay measures the absorbance of the 
reaction which allows the activity to be expressed as (μU/μl). The Buffer for the ACP assay 
was  
(.5 M) sodium acetate (CH3COONa) (MW=82.03g/mole) the PH was adjusted to PH=5.2 
and 0.5M sodium tartrate (MW=150.09 g/mole), and 0.67M pNPP solution (p-Nitro-







2: Histological analysis : 
 
 
A. H&E staining in mouse calvaria Ex-vivo cultures:  
At the End of each trial (21,29 and 49 days) 2 calvarias from each treated group and 
controls were fixed in 10% formaldehyde, decalcified, embedded in paraffin, sectioned at 
4um and stained with hematoxylin and eosin  (H & E) for histological analysis 
 
B. Masson Tri-Chrome and picrosirius red staining in mouse calvaria Ex-vivo 
cultures:  
2 sections from each histological sample collected were stained with Masson Tri-Chrome 
and Picrosirius red to observe the new collagen matrix formed on the calvaria. 
 
 
C.  RUNX2 antibody staining in mouse calvaria Ex-vivo cultures:  
2 sections from each histological sample collected were stained with RUNX2 antibody to 










Biochemical data are presented as mean ± S.D. The statistical significance of the differences 
between    controls versus treatment groups and between different treatments were evaluated using 
ANOVA with post hoc all pair Tukey     HSD to assess the where the significance lies. The 

























Quantitative analysis of Tartrate resistant acid phosphatase (TRAP) 
activity and Alkaline phosphatase (ALP) Activity. 
 
Results of  trials 1, 2, and 3 were combined for biochemical analyses. 
For trials #1 (21 days) day 1-21, N=15 
For trials #2 (29 days) day21-29, N=10 
For trials #3 (49 days) day 29-49, N=5 
 
No TRAP activity was detected. 
 
Figure 15 displays measures of ALP activity on day 7. In this figure a significant 
increase of Osteoblast activity in AGF group compared to PDGF groups is 
suggested after 1 dose of each stimulant. Furthermore, when AGF is added 4 times 
over 7 days a significant increase in osteoblast activity was observed compared to 
1 dose of AGF. 










Figure 15 ALP activity sample from day 7: AGF increased osteoblasts activity compare to PDGF 
and controls. AGF when added in multiple doses increased osteoblast activity. However, this is 













When a single dose of AGF or PDGF was used, a significant increase of AGF-ALP 
activity over all groups was noted on day 5 and 7. A drop of ALP activity was 




Figure 16 ALP activity for single dose of GFs. A single dose of AGF significantly increased 










There was significant increase in ALP activity from day 3 until day 21 in the 
calvaria treated with 4 doses of amniotic growth factors compared to the PDGF-
bb multiple doses group and controls (figure 17). This elevated ALP activity was 
sustained until day 27 for AGF group but a drop in the activity in all other groups 
was observed after day 11. 
 
 
Figure 17 ALP activity for multiple doses of GFs. 4 doses of AGF significantly increased 









Image analysis (21 days samples)  
Images for comparison of macro photography and SEM were chosen from the 21 day 
samples prior to tissue processing for histology. Calvaria were documented after fixation 
to evaluate the differences in texture and the appearance of the defect/membrane 
interface for each treatment. In the defect only sample the clear outline of the critical 
size defect produced by the sharp tissue punch clearly is outlined (figure 18). Calvaria 
treated with collagen membrane only and calvaria treated with PDGF-bb were observed 
to have a distinguishable membrane periphery from the surrounding bone and clear 
membrane texture (figure 19,20). In contrast the periphery of the membrane/defect 
interface in AGF group blend homogenously with surrounding bone and the membrane 
bridges are completely masked by the new dome like tissue. (Figure 21). In (figure 22) 
we can see the difference between calvaria treated with AGF dense white (left) 







Figure 18 photo. Calvaria with critical size defect (2mm punch) the arrow indicates the clear cut 








Figure19 photo. Calvaria with non-crosslinked collagen membrane: lack of crosslinking  allows 
for cell migration through spaces toward the defect center. Left arrow shows the collagen 












Figure 20 photo. Calvaria defect treated with collagen membrane + PDGF-BB: Membrane can 
be distinguished from surrounding bone. Left arrow shows the collagen membrane. Right arrow 








Figure 21 photo. Calvaria defect treated with collagen membrane + AGF: New dome of tissue 




















Scanning electron Microscopy(SEM) (21 days samples): 
magnification (22x,200x and 500x) 
Scanning electron microscopy is a great tool to explore these surface textures and 
conditions. Calvaria with defect only at day 21 showed the clear cut margin of the defect. 





Figure 23. Defect only calvaria of 21 days specimen: which shows the clear cut defect border at 




Figure 24. Edge of Defect only calvaria 21 days specimen: Clear border of the defect 






Figure 25. Defect only at 21 days calvaria surface away from edge : arrow shows Osteoblast like 













In the collagen membrane only group, there is a clear difference in the surface texture of the 
membrane and the surrounding bone surface (figure 26). Magnification of the edge of the defect 
area shows the bone cells migrate in the membrane spaces (figure 27). Higher magnification shows 
the spaces between the non-crosslinked membrane fibers which allow for the 20-30 microns sized 
osteoblast to migrate. (Figure 28) 
 
 
Figure 26. 21 days Calvaria with collagen membrane:  arrow show the defect/membrane 





Figure 27. 21 days  Calvaria with collagen membrane at the defect/membrane interface:  arrow 









Figure 28. 21 days calvaria with non-cross linked collagen membrane in the middle of the 












PDGF-bb treatment did not change the surface texture as the membrane is still 
distinguishable from the surrounding bone surface (Figure 29). few cells can be seen on 
the membrane surface at higher magnification (Figure 30,31). 
 
 
Figure 29. 21 days Calvaria treated with non-cross linked plus PDGF-BB: Defect/membrane 





Figure 30. 21 days Calvaria treated with collagen membrane and PDGF-BB:  Few 






Figure 31. 21 days Calvaria treated with collagen membrane Plus PDGF-BB:  Few cells 












In contrast to collagen and PDGF-BB groups, AGF calvaria showed homogenous accumulation of 
osteoblast like cells at the periphery and coverage of the collagen membrane area with new tissue 
(Figure 32). Higher magnification demonstrated the dramatic accumulation of the same osteoblast 




Figure32. 21 days Calvaria treated non-cross linked collagen membrane plus AGF: Cells 
accumulating over the  defect/membrane interface which completely masks the defect/membrane 








Figure 33. 21 days  Calvaria treated with non-cross linked collagen membrane plus AGF: 
Dramatic accumulation of osteoblast like cells on the defect/membrane interface at x200 






Figure 34. 21 days Calvaria treated with collagen membrane plus AGF:  Dramatic accumulation 














Histological analysis: HE (21 Days samples): 
All Histological samples are from 21 days samples and the sections were not centered in the middle 
of the defect to protect the integrity of the sample. Histological analysis of calvaria with defect 
only showed that the lack of scaffold results in the lack of migration  into the defect area and 







Figure 35. 21 days Calvaria with defect only (without scaffold or growth factor). The area 








Figure 36 Calvaria with defect only: left boarder shows no migration and no new tissue 
formation beyond the edge of the original. 














The critical observation in the non-cross-linked collagen membrane only is that by just adding a 
scaffold, cells started to migrate into the defect area forming new tissue on the periphery. increased 
in thickness is shown in calvarial bone area 0.5 mm from the defect edge (Figure 37) and few cells 
are migrating on top of the membrane (Figure 38,39). Also note expansion of the collagen 
membrane when saturated and the space present in the non-crosslinked membrane. 
 











Figure 38 Calvaria defect Plus collagen membrane only: increased thickness of calvarial bone. 







Figure 39 Calvaria defect Plus collagen membrane only:  Cells and matrix extended past the 
defect margin compared to calvaria with defect only (see figure 36). A: New tissue on the 














PDGF-BB treated calvaria Had less increase in thickness compared to collagen membrane group 




Figure 40 Calvaria defect treated with collagen membrane plus PDGF-BB. The area labeled is 










Figure 41 Calvaria defect treated with collagen membrane Plus PDGF-BB (right side) shows less 










Figure 42 Calvaria defect treated with collagen membrane Plus PDGF-BB. No migration of 
matrix and cells beyond defect margin. In fact seems to have depressed cell activity seen in 















AGF treatment (Figure 43) increased the thickness of calvarial bone compared PDGF-BB and 
collagen membrane only groups (Figure 44). Magnifying the edge of the defect area shows new 
osteoid formation in the periphery of the defect extending toward the membrane (Figure 44).  
Osteoblast like cell accumulate inside and on the membrane surface which was also seen by 
Scanning electron microscope (figure 46). 
 
 
Figure 43 Calvaria defect treated with collagen membrane plus AGF. The area labeled is 








Figure 44 Calvaria defect treated with collagen membrane plus AGF (Right border): the arrow 













Figure 45 Calvaria defect treated with collagen membrane and AGF (magnified calvaria area): 









Figure 46 Calvaria defect treated with collagen membrane and AGF (magnified membrane area): 















Histological analysis: Masson Tri chrome and PSR (21 days samples) : 
All the slides shown are from 21 days samples. Histological slides were stained with 
Masson Tri chrome and PSR to visualize the new osteoid formed over the original 
calvarial bone and the collagen membrane. AGF treatment induced new collagen 
matrix formation shown by the blue color in Masson Tri chrome (figure47) and red 
with PSR in (figure 48). With more magnification the new collagen matrix can be 












Figure 47 Calvaria defect treated with collagen membrane and AGF (Masson Tri Chrome): Blue 








Figure 48 Calvaria defect treated with collagen membrane and AGF (PSR stained): The red/orange 
Color indicates collagen type 1, and the green color indicates collagen type 3. The labeled area is 









Figure 49 Calvaria defect treated with collagen membrane and AGF (Masson Tri chrome): New 






Figure 50 Calvaria defect treated with collagen membrane and AGF (PSR stained): The red Color 









Calvaria treated with PDGF-BB shows no new collagen matrix formation beyond the edge of the 





Figure 51 Calvaria defect treated with collagen membrane and PDGF-BB (Masson Tri chrome) 
show no new collagen formation beyond the edge of the defect and minimal over the old bone. 









   
Figure 52 Calvaria defect treated with collagen membrane and PDGF-BB (PSR stained) show 
no new collagen formation beyond the edge of the defect and minimal over the old bone: the red 
color indicates collagen type 1, and the green color indicates collagen type 3. The labeled area is 







Figure 53 Calvaria defect treated with collagen membrane and PDGF-BB (Masson Tri chrome): 
new matrix formation only on the calvaria bone surface not beyond the edge or over the membrane 













Figure 54 PSR stained Calvaria treated with PDGF-BB show no new collagen formation beyond 
the edge of the defect and minimal over the old bone: The red Color indicates collagen type 1, and 













Histological analysis: Immunofluorescence (21 days samples): 
 
To confirm that osteoblasts are present in the HE sections, slides were stained with 
anti RUNX2 which is an active osteoblast marker (Figure 56). Rabbit IgG was used 
as a negative control to identify nonspecific background (Figure 55). 
RUNX2 positive signal is indicated by the red color. In the AGF group the positive 
signal is present around the blue nucleus (DAPI) stain in the middle and over the 
collagen membrane (Figure 57) compared to no signal inside and on the membrane 
of PDGF group (Figure 59). The positive signal is also present on the new osteoid 















Figure 55 AGF calvaria with IgG negative control 
 
 

















Figure 57 AGF treated calvaria : The red signal of RUNX2 is distributed on the surface of 






Figure 58 AGF treated calvaria : Positive signal of RUNX2 can be seen around nucleus of 
osteoblast cell on the surface of collagen membrane and on the surface of calvaria 
 
Figure 59 PDGF treated calvaria have only positive signal strictly on the surface of calvarial 








Earlier studies46,48,49,56 discussed regeneration using a single growth factor. This study investigated 
the potential for new bone formation using multiple growth factors derived from human amniotic 
membrane (Amniospark) (AGF) in ex-vivo calvaria cultures. In addition, we tested stimulatin of 
bone formation with multiple doses of AGF in comparison with multiple doses of a single growth 
factor (PDGF-BB). The null hypothesis was that delivery of human amniotic membrane growth 
factors into a scaffold would fail to promote osseous regeneration.  
In our study growth factors were added directly over the scaffold to mimic an in vivo condition. 
Calvaria were treated with either a single dose or multiple doses applied on 0,3,5 and 7 days.  
 
Non-crosslinked membrane showed expansion allowing for an intimate interface between the 
calvaria and the membrane which created a bridging effect unlike the crosslinked membrane which 
showed more size stability and led to a gap between the membrane and the defect edge. The use 
of non-cross linked collagen membrane as a scaffold revealed that the size of spaces between the 
membrane fibers (Figure 28) are larger than the mesenchymal cells and allows for cell migration. 
The membrane was held in place by its expansion toward the defect edge after soaking with the 










Multiple doses of Amniotic growth factor gave sustained input to mimic the in-vivo conditions.  
Calvaria treated with multiple doses of AGF showed a significant increase in ALP activity 
compared to a calvaria treated with a single dose of AGF or  to single and multiple doses of PDGF-
BB or controls. The ALP enzyme is increased when osteoblasts are producing new matrix which 
was later confirmed by histological analysis.  
 
The ALP analysis for PDGF-BB showed a decrease of ALP activity compared to all groups which 
corresponds with previous reports stating that PDGF-BB inhibits differentiation and matrix 
formation in bone cells but increases proliferation49. This effect is transient and leads to increase 
numbers in cells which eventually could enhance bone formation.  The most startling observation 
from this analysis was that the effect of a pulsed dosage of AGF lasted two weeks, whereas the 
effect of a single dose lasted only five days. A possible explanation for this phenomena is that each 
dose of AGF  with its multiple growth factors given at different time intervals may have a cascade 
effect, resulting in a separate chain of events. An alternate theory is that the total volume of the 
doses administered increased the duration of the impact. 
 
Macro photography showed dome like new tissue formation formed over the scaffold of AGF 
treated calvaria which completely masked the scaffold periphery by day 21 which mirrors the 
biochemical findings in the  ALP data. In PDGF-BB treated and scaffold alone calvaria, the 
membrane and periphery can still be distinguished from surrounding bone which reflects minimal 





The SEM photographs show cell accumulation and migration of cells in AGF treated calvaria. In 
contrast PDGF-BB treated calvaria display no cell migration over the scaffold.  
 
Histological analysis also showed complete coverage of the defect in the AGF group with new 
tissue formation beyond the defect edge, round cells accumulation over the scaffold, and increased 
thickness of the old bone. In contrast, PDGF-BB had minimal round cell migration with minimal 
increase in bone thickness and no new tissue formation beyond the defect edge However it shows 
increase number of cells which collaborates previous studies in in vivo cell cultures stating that 
PDGF-BB added in multiple doses inhibited migration and differentiation  but induced 
proliferation49. 
 
RUNX2, an osteoblast activity marker, was used to confirm the cell type observed in histological 
sections.  The positive RUNX2 signal can be seen clearly in AGF treated calvaria around the DAPI 
nucleolus stain (figure 58)  both inside and over the collagen membrane. In PDGF-BB treated 
calvaria the signal can only be detected in the periosteal layer.  
 
This study shows the rapid formation of new tissue and complete coverage of a critical size defect 
in 3 weeks. This has not been shown in previous studies in our laboratory using a single factor 
such as PDGF-BB or BMP-2 with the same 3D calvaria model.  
 
The ability to stimulate regeneration is likely due to the synergy of multiple growth factors in AGF. 
These growth factors induce migration of mesenchymal cells and promote proliferation. The 




necessary for new tissue formation and new collagen matrix was confirmed  in PSR and Masson 





Amnion multiple growth factors were compared to the established single growth factor PDGF-BB 
which previously showed a robust regenerative response49.  In intact human models complete 
coverage of osseous defects occurred in dogs after 3 weeks.45PDGF-BB improved clinical 
attachment gain by 6.17 mm as well as regeneration of bone, PDL, and cementum in a human 
study .49 IGF-1  stimulated growth in tibial growth in rats.57 In dogs bFGF  significantly enhanced 
periodontal regeneration in 3 wall defects and class II furcation defects without ankylosis or 
epithelial downgrowth.58 All of these growth factors have the ability to promote regeneration 
through mesenchymal cells. 
 
Mouse calvaria provide an excellent system for study of osseous regeneration when testing new 
material on critical defects. They are similar to the maxilla in having  a relatively poor blood 
supply, quantity of existing bone, and intramembranous ossification.59 
The calvaria ex vivo model allows separation of  bone remodeling stages into either bone formation 
with the addition of ascorbic acid or resorption with the addition of PTH. 60 The effect of growth 
factors can  be studied in this confined  system without the endogenous growth factors present in 







Though our results are encouraging they stimulate further questions. First, is it  necessary to assess 
the reproducibility of the regenerative responses to AGF in an intact organism containing 
periosteum, vasculature and nerves. Second, evaluation of later time points in an in vivo model 
may determine whether  the immature osteoid observed histologically will  be resorbed or 
mineralized forming mature bone. Finally the AGF should be analyzed for its contents and 
followed by testing of the components alone and in combinations in the same calvarial model. 
Within the limitations of this study, the use of amniotic growth factors (AGF) appears to have 
the potential to enhance calvaria bone regeneration in ex-vivo cultures. The results of multiple 
biological and histological analyses emphasize that multiple growth factors are a viable 
candidate for osseous regeneration and that a pulsed application of AGF yields more osteoblast 














1. Biochemical analyses:  
 
Quantitative measures of alkaline Phosphatase (ALP) activity and tartrate  
resistant acid phosphatase (TRAP) from calvarial bones media: 
Reagent preparation for ALP: 
Add 1:99 MgCl2 with 0.2 Tris-HCL (99) to 0.67M pNPP (1) 
Assay: 
1. Add 20ul of samples to each well in 96 well plate 
2. Add 100ul of prepared Reagent  
3. Incubate for 18 hours at 37ºC  
4. Add 100µl of stop solution (0.5 NaOH) 
5. Measure the absorbance at 450nm wavelength 
 
 
Figure 60 ALP and TRAP reaction which allows for quantification of ALP and TRAP enzyme 






Quantitative measures of tartrate resistant acid phosphatase (TRAP) and 
alkaline Phosphatase (ALP) activity from calvarial bones media: 
Preparation of the reagent for ACP: 
1. Add 1/10 volume of pNPP solution to Sodium tartrate.  
2. 1:9, 0.5 sodium tartrate with pNPP (1) and sodium acetate (9). 
 
TRAP Assay: 
1. Add 20ul of sample to each 96 well  
2. Add 100ul of assay reagent  
3. Incubate for 5 hours at 37°C 
4. Add 80ul stop solution (0.5M NaOH) 











2.Scanning Electron Microscopy sample preparation: 
 
1. Primary fixation with 2.5% glutaraldehyde in 0.1M PBS for 30 mins 
2. Washing with 0.1 PBS for 5-10 mins X3 
3. Secondary fixation with 2% osmium tetroxide in distilled water for 20 mins 
4. Washing with 0.1 M PBS for 5-10 mins X3 
5. Dehydration as mentioned in histology dehydration  
6. 10 mins in 50% ethanol and 50% HDMS X2 
7. !0 mins in 100% HDMS X2 
8. Air dry over night  
9. Dry completely under vacuum for 20-60 mins 
10. Mount on SEM Stop with silver paste 












 Preparation of microscope slides: 
 
A. Fixation: 
Tissue was fixed with 4% paraformaldehyde for 48 hours at 4°C and then stored in 70% 
EtOH at 4°C. 
 
B. Decalcification: 
The tissues placed in the decalcification solution (mixture of 107.88g of 
EDTA Na2*2H2O and 0.8g of NaOH (salt) in water; PH= 5.0) and left 











The tissues dehydrated and paraffinized with the following sequence: 
1. Water 
2. 45 minutes 70% Alcohol 
3. 45 minutes 80% Alcohol 
4. 45 minutes 95% Alcohol 
5. 45 minutes 100% Alcohol 
6. 60 minutes 100% Alcohol 
7. 60 minutes 100% Alcohol 
8. 60 minutes Clearing Reagent (xylene or substitute) 
9. 60 minutes Clearing Reagent (xylene or substitute) 
10. 60 minutes Paraffin 1 
11. 60 minutes Paraffin 2 










Block is sectioned with 4 microns thickness and is put on the slide Allow the slides to dry overnight 




 Deparaffinization for Staining: 
1. 2X5 min Xylene 
2. 1X5 min 100% EtOH 
3. 2X5 min 95% EtOH 
4. 1X5 min 85% EtOH 
5. 1X5 min 75% EtOH 













1. Placed the slides in the Hematoxylin solution and stain for 3 minutes 
2.  Rinse in tap water until excess hematoxylin washes of 
3.  Rinse the slides in 0.1 % HCL solution [tissues will take a slight red color] 
4.  Rinse in tap water to clear off excess HCL 
5.  Rinse the slides in 0.6% ammonium [until tissues take blue color] 
6.  Wash off excess ammonium in tap water  
7.  Place the slides in 85% alcohol to dehydrate  














 Masson Trichrome stain: 




2. Cool with tap water until 18-26°C 
3. Remove yellow color with running tap water 
4. 5 mins hematoxylin  
5. 5 mins running tap water 
6. Rinse in dH2O  
7. 5 mins scarlet red Fucshin 
8. Rinse in dH2O 
9. 5 mins P/P Acid 
10. 5 mins Aniline Blue  
11. 2 min Acetic Acid 1% 








 PSR stain: 
1. Deparaffinize sections if necessary and hydrate in distilled water.  
 
2. Apply adequate Picro-Sirius Red Solution to completely cover the tissue section and 





3. Rinse slide quickly in 2 changes of Acetic Acid Solution.  
 
4. Rinse slide in absolute alcohol.  
 
5. Dehydrate in 2 changes of absolute alcohol.  
 
6. Clear slide and mount in synthetic resin. 
 
 
 RUNX2 Stain for Immunofluorescence:  
1. Wash sections in dH2O three times for 5 minutes each. 
2. Incubate sections in 3% hydrogen peroxide for 10 minutes. 
3. Wash sections in dH2O twice for 5 minutes each. 
4. Wash sections in 1X TBS/0.1% Tween-20 for 5 minutes. 
5. Block each section with 100-400 µl TBST/5% normal goat serum for 1 hour at room 
temperature. 
6. Remove blocking solution and add 100-400 µl RUNX2 antibody. Incubate overnight at 
4°C. 
7. Remove antibody solution and wash sections in wash buffer three times for 5 minutes each. 
8. Add 100-400 µl biotinylated secondary antibody. Incubate 30 minutes at room 
temperature. 
9. Remove secondary antibody solution and wash sections three times with wash buffer for 5 
minutes each. 





11. Remove ABC reagent and wash sections three times in wash buffer for 5 minutes each. 
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